1300002E11Rik Inhibitors
Chemical inhibitors of the protein encoded by the gene 1300002E11Rik are known to interfere with cell cycle progression and transcription regulation by targeting various cyclin-dependent kinases (CDKs). Palbociclib and ribociclib are two such inhibitors that selectively inhibit CDK4 and CDK6. The inhibition of these kinases by palbociclib or ribociclib can lead to a halt in the G1-S phase transition within the cell cycle, thus affecting the functional role of the protein 1300002E11Rik if it is involved in this critical phase of cell division. Similarly, abemaciclib, which also selectively inhibits CDK4 and CDK6, can disrupt the function of this protein by preventing the progression from the G1 phase to the S phase of the cell cycle.
Other inhibitors like alsterpaullone and purvalanol A target CDK1 and CDK2, which are integral for the advancement of the cell cycle beyond the G1 phase and into the S phase, and also for the transition from G2 to the mitotic phase. The protein encoded by 1300002E11Rik, being potentially involved in cell cycle regulation, can be functionally inhibited by these substances through their action on these kinases. Dinaciclib and milciclib offer a broader range of inhibition, affecting not only CDK1 and CDK2 but also CDK5 and CDK9, which are crucial for both cell cycle control and transcription regulation. The functional activities of the protein 1300002E11Rik, thus, can be inhibited by these inhibitors if it is part of pathways regulated by these kinases. Flavopiridol, known primarily for its inhibition of CDK9, would affect the protein function related to transcription processes governed by this kinase. AZD5438, which inhibits CDK1, CDK2, and CDK9, would similarly interfere with the function of the protein 1300002E11Rik in both cell cycle progression and transcriptional regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib selectively inhibits cyclin-dependent kinases CDK4 and CDK6. Since 1300002E11Rik is involved in cell cycle regulation, palbociclib's inhibition of CDK4/6 would lead to a halt in cell cycle progression, thereby inhibiting the functional role of 1300002E11Rik in cell cycle control. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a potent inhibitor of cyclin-dependent kinases. It can inhibit CDK1, which is critical for cell cycle progression. By targeting CDK1, alsterpaullone disrupts the cell cycle, potentially inhibiting 1300002E11Rik function if 1300002E11Rik's role is linked to cell cycle processes regulated by CDK1. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine specifically inhibits several cyclin-dependent kinases such as CDK1, CDK2, CDK5, and CDK9. If 1300002E11Rik is involved in cell cycle phases regulated by these kinases, roscovitine's inhibition of these kinases would result in the inhibition of the functional activities of 1300002E11Rik. | ||||||
Purvalanol B | 212844-54-7 | sc-361300 sc-361300A | 10 mg 50 mg | $199.00 $846.00 | ||
Purvalanol A is a selective inhibitor of cyclin-dependent kinases. By inhibiting CDKs, particularly CDK1 and CDK2, it disrupts cell cycle progression. As 1300002E11Rik has a role in cell cycle regulation, purvalanol A's inhibition of CDKs would functionally inhibit the activities of 1300002E11Rik. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib strongly inhibits several CDKs, including CDK1, CDK2, CDK5, and CDK9. Its action on these kinases, which are integral to cell cycle progression and transcription, would inhibit the function of 1300002E11Rik if 1300002E11Rik is a part of these cell cycle or transcription regulatory pathways. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 is an inhibitor of CDK1, CDK2, and CDK9. The inhibition of these kinases, which are involved in cell cycle and transcription regulation, would lead to a functional inhibition of 1300002E11Rik assuming 1300002E11Rik is active in these processes. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits several CDKs, most notably CDK9 which is key for transcription elongation. If 1300002E11Rik's function is related to transcription processes governed by CDK9, then flavopiridol's inhibition of CDK9 would result in functional inhibition of 1300002E11Rik. | ||||||